Skip to main content
ICLR logo

ICON Public Limited Company (ICLR) Stock: Price, Forecast & Analyst Target

ICON Public Limited Company (ICLR) — MoonshotScore 73/100 (Strong band), calculated Nov 18, 2026. Price $190.36 (-2.46%), as of the Nov 19, 2026 trading session; market cap $14.3B.

Educational signal · not a buy or sell recommendation · How to read this

$190.36 −$4.80 (-2.46%) Market Cap $14.3B

ICON Public Limited Company · ICLR · NASDAQ · Healthcare · Medical - Diagnostics & Research

Research dated 2026-09-13 (results through Q2 FY2026; Q3 FY2026 not covered): ICON runs clinical development programs for drug, biotechnology, medical-device and public-health customers, combining study execution with laboratories, data, staffing and commercialization support. The share case rests on whether resilient demand can restore profit conversion while cash generation carries a debt-heavy capital structure.

Price as of Nov 19, 2026

Key Statistics

73 of 100

MoonshotScore v2 · ICON Public Limited Company (ICLR)

Strong
Business Quality Solid (70)
Financial Safety Okay (51)
Valuation Fair (75)
Growth Durability Flat (43)
Momentum Surging (93)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, though the balance sheet and growth are only middling; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Flat; Momentum: Surging.

  • quarterly revenue $2.02B (Q3 FY2026, quarter ended Sep 30, 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z 2.14 · Piotroski F 7

Helping: business quality, an attractive price, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ICLR (52 recorded, newest six shown)
RecordedScoreBand
72Strong
73Strong
72Strong
72Strong
73Strong
73Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$190.36
Change on the day-2.46%
52-week range$66.57–$219.04
Market capitalisation$14.3B—
Price / earnings (trailing)33.34
Shares traded on the day939.7K
Beta (volatility vs the S&P 500)1.19

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $93, high $211, latest $190. $211 $93 high $211 Oct 17, 2025 Nov 19, 2026 · $190 $185Oct 17, 2025$172Oct 31, 2025$162Nov 14, 2025$185Nov 28, 2025$187Dec 12, 2025$183Dec 26, 2025$181Jan 9, 2026$187Jan 23, 2026$151Feb 6, 2026$100Feb 20, 2026$107Mar 6, 2026$100Mar 20, 2026$114Apr 2, 2026$120Apr 17, 2026$113May 1, 2026$116May 15, 2026$136May 29, 2026$146Jun 12, 2026$170Jun 26, 2026$168Jul 10, 2026$166Jul 24, 2026$165Aug 7, 2026$172Aug 21, 2026$165Sep 4, 2026$164Sep 18, 2026$162Oct 2, 2026$170Oct 16, 2026$211Oct 30, 2026$195Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for ICON Public Limited Company (ICLR): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Neutral
Valuation Moderate
Growth Durability Neutral
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Neutral
ROE Weak
Gross Margin Weak

Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is ICON Public Limited Company (ICLR), and what does it report?

Short answer · as of

ICON is a clinical research organization, not primarily a seller of diagnostic tests.

Customers outsource the design, management and analysis of clinical programs, along with laboratory work, patient and site access, staffing, data services and post-market support.

Reported revenue therefore measures a broad portfolio of development services delivered across regions and customer types. The consolidated results reflect the economics of that service platform: substantial revenue can coexist with much thinner net profit when delivery costs and operating expenses absorb more of the gross profit pool.

2 · Latest results

What do the latest results show for ICON Public Limited Company (ICLR)?

Short answer · as of

The most recent reported quarter, Q3 FY2026, carried revenue of $2.02B.

The latest period brought sequential revenue growth and a result above the market estimate. Gross profit and net income nevertheless fell, while operating profit improved, leaving a split picture: demand held up better than profitability available to shareholders.

Management kept its annual revenue and adjusted earnings guidance unchanged. That stance is a management expectation rather than evidence that the recent gross-profit pressure has cleared, especially after annual revenue was broadly steady while annual net income contracted sharply.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2026$2.02B$122M$1.58 (diluted)
Q2 FY2026$2.06B$73M$0.94 (diluted)
Q1 FY2026$2.03B$105M$1.36 (diluted)
Q4 FY2025$2.11B$149M$1.93 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for ICON Public Limited Company (ICLR)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Operating cash flow has remained positive across the displayed periods, and recent cash accumulation has strengthened liquidity. Capital spending has consumed far less cash than operations produced in most periods, supporting healthy free-cash-flow conversion despite uneven reported earnings.

Debt still exceeds cash and investments by a wide margin, while near-term liquidity ratios sit close to full coverage rather than offering a deep cushion. ICON is therefore exposed less to immediate cash burn than to sustained profit compression or weaker cash conversion that would reduce room to manage leverage.

The business risk is tied directly to outsourced clinical activity: less study execution, laboratory work, staffing or post-market support would pressure utilization across a large service workforce. Because the platform spans many linked services, weaker customer program activity can reach revenue, margin and cash generation together.

4 · What to check next?

What should you watch next at ICON Public Limited Company (ICLR)?

Short answer · as of

Current published price targets run low $105.00 · high $268.00 · consensus $217.50 · median $232.50 against a quoted price of $190.36 (as of Nov 19, 2026).

The next result should be judged through the relationship among revenue, gross profit and operating cash flow. Revenue holding near recent levels would matter less if gross profit continues to contract or cash conversion weakens.

Watch whether performance remains compatible with unchanged management guidance and with market estimates that assume renewed revenue and earnings growth over the forecast horizon. Continued cash accumulation would improve financial flexibility; debt reduction would provide a stronger confirmation that operating cash is reaching the balance sheet.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does ICON Public Limited Company compare with its peers?

Short answer

ICON Public Limited Company's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

ICON competes as a broad clinical-development partner rather than a narrow laboratory or staffing vendor. Its offering connects trial design and execution with data, imaging, language, laboratory, patient-access and commercialization services, while supporting full-service engagements and functional service partnerships.

That breadth makes delivery scale and workforce utilization central to the comparison with more specialized research providers. ICON’s attraction is the ability to serve more of a customer’s development program; the tradeoff is that weak profit conversion across a large platform can outweigh stable consolidated revenue.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Neurocrine Biosciences, Inc. (NBIX) Named competitor$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Mettler-Toledo International Inc. (MTD) Same industry, near in market value$1705.66 Nov 19, 2026$33.9B93 5-pillar Nov 18, 2026
Medpace Holdings, Inc. (MEDP) Named competitor$633.98 Nov 19, 2026$17.7B92 5-pillar Nov 18, 2026
Illumina, Inc. (ILMN) Same industry, near in market value$210.01 Nov 18, 2026$31.8B84 5-pillar Nov 18, 2026
Qiagen N.V. (QGEN) Same industry, near in market value$49.63 Nov 19, 2026$10.3B83 5-pillar Nov 18, 2026
Quest Diagnostics Incorporated (DGX) Same industry, near in market value$258.99 Nov 19, 2026$28.5B74 5-pillar Nov 18, 2026
ICON Public Limited Company (ICLR) — this page$190.36$14.3B73
Revvity, Inc. (RVTY) Same industry, near in market value$151.59 Nov 19, 2026$16.9B71 5-pillar Nov 18, 2026
Labcorp Holdings Inc. (LH) Same industry, near in market value$370.78 Nov 18, 2026$30.1B71 5-pillar Nov 18, 2026
Charles River Laboratories International, Inc. (CRL) Same industry, near in market value$327.93 Nov 19, 2026$15.7B70 5-pillar Nov 18, 2026
The Cooper Companies, Inc. (COO) Named competitor$60.33 Nov 19, 2026$11.5B40 5-pillar Nov 18, 2026
Natera, Inc. (NTRA) Same industry, near in market value$289.50 Nov 18, 2026$42.0B36 5-pillar Nov 18, 2026
Twist Bioscience Corporation (TWST) Same industry, near in market value$111.62 Nov 19, 2026$7.61B35 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$105.00 – $268.00
Consensus target
$217.50
Median target
$232.50

Consensus record · Captured .

Measured against a quoted price of $190.36 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
60
Identified insiders
9
Purchases
0
Sales
37
Other transactions
23

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ICLR in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.10%$22.84MNew position

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about ICON Public Limited Company (ICLR)?

Read these with our analysis →

ICLR Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

Does ICON’s laboratory offering make it a diagnostics company?

ICON uses laboratory services inside a wider outsourced clinical-development platform. Its work extends from program design and study execution through patient access, data analysis and post-market commercialization.

Why did ICON’s latest revenue beat not produce stronger profit?

Revenue exceeded the market estimate, but gross profit and net income declined from the preceding period. The result shows that customer activity and shareholder profit conversion did not move together.

How do ICON’s full-service partnerships turn study activity into cash?

Full-service and functional partnerships let ICON provide labor, laboratories, data and trial operations across customer programs. Recent positive operating cash flow shows that this service activity is converting into cash, although the amount has varied materially between periods.

What does ICON’s Advarra alliance add to its trial-site model?

The alliance is intended to develop a connected network of research-ready clinical trial sites. It complements ICON’s existing site and patient access services rather than changing the company into a site owner.

What is the ICLR stock price today?

The last price recorded for ICON Public Limited Company (ICLR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ICLR price target?

The analyst consensus price target for ICON Public Limited Company (ICLR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 26 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Management outlook — dated call excerpts
  • 1. What is ICON Public Limited Company (ICLR), and what does it report?: Sector / industry (provider taxonomy); Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Employees
  • 2. What do the latest results show for ICON Public Limited Company (ICLR)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Trailing twelve-month ratio set
  • 3. What are the financial strengths and risks for ICON Public Limited Company (ICLR)?: Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Business description; Employees
  • 4. What should you watch next at ICON Public Limited Company (ICLR)?: Next earnings report; Analyst revenue and earnings estimates (average); Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt
  • 5. How does ICON Public Limited Company compare with its peers?: Business description; Employees; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Operating cash flow by quarter (USD millions)
  • FAQ: Does ICON’s laboratory offering make it a diagnostics company?: Sector / industry (provider taxonomy); Business description
  • FAQ: Why did ICON’s latest revenue beat not produce stronger profit?: Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands)
  • FAQ: How do ICON’s full-service partnerships turn study activity into cash?: Business description; Operating cash flow by quarter (USD millions)
  • FAQ: What does ICON’s Advarra alliance add to its trial-site model?: Business description
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold ICLR

Funds in our ETF coverage that list ICLR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares MSCI Ireland ETF (EIRL)4.96%